Method for Treating Oncological, Virulent and Somatic Diseases, Method for Controlling Treatment Efficiency, Pharmaceutical Agents and Composition for Carrying Out Said Treatment

a technology for virulent and somatic diseases and oncology, applied in the field of medicine and veterinary science, can solve the problems of insufficient therapeutic effect and lack of data about the genetic repertoire of dna, and achieve the effect of increasing the efficacy of traditional therapeutic methods

Inactive Publication Date: 2008-01-03
GENKIN DMITRY DMITRIEVICH +1
View PDF1 Cites 34 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0024] Destruction or inactivation of free blood plasma circulating DNA will lead to inability of tumor cells to maintain necessary level of genetic variability in organism and loss ability to maintain “malignant phenotype” (growth, metastasing, insensitivity to therapy). Such therapeutic intervention has its own therapeutic value as well as it increases efficacy of traditional therapeutic methods.

Problems solved by technology

The long term experience from clinical application of such therapy has shown that due to high genetic placticity the most malignant cells become insensitive to the specific therapy used before malignant neoplasm could be completely destroyed by said therapy.
The effect they find was therapeutically insufficient.
Moreover, therapy disclosed by authors was trended against phagocytosis of nucleosomes on the surface of tumor cells and that exclude the possibility of therapeutic regimes sufficient for binding and removal of circulating blood plasma DNA.
Thus, there is no data available about genetic repertoire of DNA which circulates in blood plasma of patients with oncopathology, infections, somatic pathology and healthy people, about the biological role of of blood plasma circulating DNA and about possible therapeutic effect of blood plasma circulating DNA destruction or inactivation in these diseases treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for Treating Oncological, Virulent and Somatic Diseases, Method for Controlling Treatment Efficiency, Pharmaceutical Agents and Composition for Carrying Out Said Treatment
  • Method for Treating Oncological, Virulent and Somatic Diseases, Method for Controlling Treatment Efficiency, Pharmaceutical Agents and Composition for Carrying Out Said Treatment
  • Method for Treating Oncological, Virulent and Somatic Diseases, Method for Controlling Treatment Efficiency, Pharmaceutical Agents and Composition for Carrying Out Said Treatment

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0083] Influence of DNase I Administrated Twice a Day on Erlich Tumor Growth at Mice

[0084] Group 1—10 mice transplanted with Erlich carcinoma (control).

[0085] Group 2—10 mice transplanted with Erlich carcinoma. Mice were intraperitoneally injected with DNase at 1 mg / kg dose in 200 ml of phosphate buffer twice a day starting from 3 up to 7 day after tumor transplantation.

[0086] Group 3—10 mice transplanted with Erlich carcinoma. Mice were intraperitoneally injected with DNase at 2 mg / kg dose in 200 ml of phosphate buffer twice a day starting from 3 up to 7 day after tumor transplantation.

[0087] Results of experiments were estimated according to tumor's growth inhibition (TGI) that were expressed in percents to control data received at last day of DNase injection with standard formula using.

[0088] Tumor's size on the 7 day after transplantation.

Tumor'sGroupvolumeTGI %P1 86+ / −12——233 + / − 661%p 334 + / − 760%p

[0089] The data obtained indicates that tumor's growth is significantly ...

example 2

Inhibition of Erlich Tumor Growth by Use of Different Schemes of DNase Administration

[0090] In our experiments DNA circulating in blood plasma of patients was the therapeutic target of DNase. Prolonged presence of DNase in blood plasma at catalytically effective concentrations is essential for provision of maximal therapeutic effect. According to that DNase myltiply administration should provide better therapeutic effect than the same total daily dose, administrated just as only two daily injections.

[0091] Group 1—10 mice transplanted with Erlich carcinoma (control).

[0092] Group 2—10 mice transplanted with Erlich carcinoma. Mice were intraperitoneally injected with DNase at 1 mg / kg dose in 200 ml of phosphate buffer twice a day starting from 3 up to 7 day after tumor transplantation.

[0093] Group 3—10 mice transplanted with Erlich carcinoma. Mice were intraperitoneally injected with DNase at 0.5 mg / kg dose in 200 ml of phosphate buffer four times a day starting from 3 up to 7 day...

example 3

Combined Use of DNase and Antitumor Doxorubicin Compound

[0097] Group 1—10 mice transplanted with Erlich carcinoma (control).

[0098] Group 2—10 mice replanted with Erlich carcinoma. Mice were intravenously injected with Doxorubicin at 2 mg / kg dose once a day starting from 3 up to 7 day after tumor transplantation.

[0099] Group 3—10 mice replanted with Erlich carcinoma. Mice were intravenously injected with Doxorubicin at 2 mg / kg dose once a day starting from 3 up to 7 day after tumor transplantation. As well mice were intraperitoneally injected with DNase at 0.5 mg / kg dose in 200 ml of phosphate buffer four times a day starting from 3 up to 7 day after tumor transplantation.

[0100] Group 4—10 mice replanted with Erlich carcinoma. Mice were intraperitoneally injected with DNase at 0.5 mg / kg dose in 200 ml of phosphate buffer four times a day starting from 3 up to 7 day after tumor transplantation.

[0101] Results of experiments were estimated according to tumor's growth inhibition (TG...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
volumeaaaaaaaaaa
volumeaaaaaaaaaa
Login to view more

Abstract

The invention relates to medicine and veterinary science and discloses a novel method for treating oncological, virulent and somatic diseases whose main target for therapeutic action is embodied in the form of DNA which freely circulates in blood plasma (and other liquid media) and originates from tumoral and mutant cells or cells infected by bacteria, fungi or protozoan and from different microorganisms which reside in the organism thereof. Said invention also relates to novel pharmaceutical compositions and to the use thereof for treating oncological diseases and infectious states provoked by bacteria, fungi and protozoa and non-infectious somatic diseases and states produced by accumulation of somatic mutations in cells of organism. Medicinal and immunological compositions, sorption and physico-chemical engineering and the method for using them in order to treat malignant tumors and other diseases are also disclosed.

Description

TECHNICAL FIELD [0001] The invention relates to medicine and veterinary science and discloses a novel method for treating oncological, virulent and somatic diseases when the main target for therapeutic action is embodied in the form of DNA which freely circulates in blood plasma (and other liquid media) and originates from tumoral and mutant cells or cells infected by bacteria, fungi or protozoan and from different microorganisms which reside in the organism thereof. Said invention also relates to novel pharmaceutical compositions and to the use thereof for treating oncological diseases and infectious states provoked by bacteria, fungi and protozoa and non-infectious somatic diseases and states produced by accumulation of somatic mutations in cells of organism. Medicinal and immunological compositions, sorption and physico-chemical engineering and the method for using them in order to treat malignant tumors and to prevent their relapses as well as for treatment of infections, athero...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C12Q1/68A61K38/00A61K39/00A61K39/395A61M37/00A61P43/00A61K38/43A61K38/44A61K38/46A61P35/00
CPCA61K38/48A61K39/0011A61K2039/505A61K2039/53C07K16/44A61K38/465C12Y301/21001A61K2300/00A61P35/00A61P43/00A61K9/0019
Inventor GENKIN, DMITRY DMITRIEVICHTETS, VIKTOR VENIAMINOVICHTETS, GEORGY VIKTOROVICH
Owner GENKIN DMITRY DMITRIEVICH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap